CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway
Yinan Liu, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Jin‐Yuan Shih
Topics & Concepts
OsimertinibGene knockdownCD44Cancer researchSignal transductionBiologyCell biologyEpidermal growth factor receptorMolecular biologyReceptorCellCell cultureGeneticsErlotinibLung Cancer Treatments and MutationsProteoglycans and glycosaminoglycans researchHER2/EGFR in Cancer Research